Edition:
United Kingdom

NanoCarrier signs exclusive agreement for global study on new approach of using NC-6004 to treat head and neck cancer


Friday, 20 Jul 2018 

July 20(Reuters) - NanoCarrier Co Ltd <4571.T>:Says NanoCarrier entered into a license and collaborative agreement with Orient Europharma Co Ltd <<<4120.TWO>>>(OEP), for co-development of NC-6004 with a new immunotherapy combination drug.This clinical approach will be developed at a global level in regions including United States, Europe and Asian countries(excluding Japan) for head and neck cancer patients building upon the basic agreement dated May 15, 2018.Under the terms of agreement, NanoCarrier grants OEP an exclusive license to develop NC-6004 globally for head and neck cancer, and NanoCarrier will receive a total of $8 million clinical milestone payments. 

Company Quote

433.0
4.0 +0.93%
7:00am BST